MX2020007098A - Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal. - Google Patents

Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal.

Info

Publication number
MX2020007098A
MX2020007098A MX2020007098A MX2020007098A MX2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A
Authority
MX
Mexico
Prior art keywords
pic1
subject
myeloperoxidase
inhibition
animal model
Prior art date
Application number
MX2020007098A
Other languages
English (en)
Inventor
Neel K Krishna
Kenji Cunnion
Original Assignee
Realta Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Holdings Llc filed Critical Realta Holdings Llc
Publication of MX2020007098A publication Critical patent/MX2020007098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para tratar lupus eritematoso sistémico en un sujeto en el cual una cantidad terapéuticamente eficaz de PIC1 se administra al sujeto. También se proporciona un método para el tratamiento de la lesión pulmonar aguda relacionada con la transfusión, donde se administra una cantidad terapéuticamente eficaz de PIC1 al sujeto. PIC1 puede modular la activación del sistema del complemento por el complejo inmune y la formación de NET en el sujeto. PIC1 puede también inhibir la actividad de mieloperoxidasa (MPO) en el sujeto.
MX2020007098A 2018-01-09 2019-01-08 Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal. MX2020007098A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862615183P 2018-01-09 2018-01-09
US201862681458P 2018-06-06 2018-06-06
US201862746649P 2018-10-17 2018-10-17
PCT/US2019/012659 WO2019139886A1 (en) 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Publications (1)

Publication Number Publication Date
MX2020007098A true MX2020007098A (es) 2020-11-11

Family

ID=67140101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007098A MX2020007098A (es) 2018-01-09 2019-01-08 Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal.

Country Status (11)

Country Link
US (4) US11135272B2 (es)
EP (1) EP3740074A4 (es)
JP (2) JP7031011B2 (es)
KR (2) KR20220104268A (es)
CN (1) CN112512548A (es)
AU (1) AU2019207508B2 (es)
CA (1) CA3086407A1 (es)
IL (2) IL287308B2 (es)
MX (1) MX2020007098A (es)
SG (1) SG11202006063RA (es)
WO (1) WO2019139886A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
MX2023003700A (es) * 2020-09-30 2023-04-21 Realta Life Sciences Inc Peptidos y metodos de uso.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625049A (en) 1993-05-12 1997-04-29 Us Health Nucleic acids encoding human astrovirus serotype 2
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU2729400A (en) 1999-01-19 2000-08-07 James Daly Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
US6696562B1 (en) 2000-07-10 2004-02-24 The United States Of America As Represented By The Secretary Of Agriculture Avian astrovirus
DE602004021946D1 (de) 2003-09-05 2009-08-20 Tonen Sekiyukagaku Kk Verfahren zur herstellung einer mikroporösen folie aus thermoplastischem harz
US20070116672A1 (en) 2003-09-05 2007-05-24 Kotwal Girish J Treatment of rheumatic diseases
US7638481B2 (en) 2003-09-05 2009-12-29 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7381524B2 (en) 2003-10-10 2008-06-03 Wisconsin Alumni Research Foundation Method to detect antibodies specific for type-2 turkey astrovirus
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2007259287B2 (en) 2006-06-15 2013-05-02 Realta Holdings, Llc Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
EP2069399A2 (en) 2007-04-11 2009-06-17 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US20130183662A1 (en) 2010-04-22 2013-07-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
US10005818B2 (en) 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
CA2804998C (en) 2010-07-21 2018-11-13 Eastern Virginia Medical School Peptide compounds to regulate the complement system
JP2015512370A (ja) 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１−阻害剤のポリマーコンジュゲート
ES2875498T3 (es) 2015-06-26 2021-11-10 Realta Holdings Llc Compuestos de péptidos sintéticos y procedimientos de uso

Also Published As

Publication number Publication date
JP2022068323A (ja) 2022-05-09
SG11202006063RA (en) 2020-07-29
IL287308A (en) 2021-12-01
CA3086407A1 (en) 2019-07-18
IL275867B (en) 2022-01-01
US20190209660A1 (en) 2019-07-11
JP2021509916A (ja) 2021-04-08
WO2019139886A1 (en) 2019-07-18
IL287308B1 (en) 2023-11-01
JP7031011B2 (ja) 2022-03-07
JP7341268B2 (ja) 2023-09-08
US20230321201A1 (en) 2023-10-12
AU2019207508B2 (en) 2024-05-02
US11712462B2 (en) 2023-08-01
EP3740074A1 (en) 2020-11-25
CN112512548A (zh) 2021-03-16
US20210252113A1 (en) 2021-08-19
KR102420552B1 (ko) 2022-07-13
EP3740074A4 (en) 2021-10-13
KR20220104268A (ko) 2022-07-26
US11020460B2 (en) 2021-06-01
US20200230212A1 (en) 2020-07-23
KR20200138168A (ko) 2020-12-09
IL275867A (en) 2020-08-31
IL287308B2 (en) 2024-03-01
AU2019207508A1 (en) 2020-07-09
US11135272B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
MX2020007098A (es) Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal.
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
SG10201900886RA (en) Methods and therapeutic combinations for treating tumors
MX2018008515A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias.
MX2019000286A (es) Una combinación farmacéutica y método para la regulación del microentorno tumoral e inmunoterapia.
PH12020551976A1 (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
MX2018008624A (es) Metodo para tratar glomerulopatia c3.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2022003194A (es) Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2020005182A (es) Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019013862A (es) Terapia de combinacion.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
MX2021015937A (es) Inhibicion de sirp-gamma para el tratamiento del cancer.
MX2021012398A (es) Metodos de terapia antitumoral.
JOP20210140A1 (ar) معالجة متلازمة الحذف 22q11.2 بكانابيديول
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
MX2021004291A (es) Tratamiento del adenocarcinoma pancreatico metastasico.
BR112022009259A2 (pt) Métodos para tratar, inibir ou eliminar um câncer em um indivíduo
ATE8322T1 (de) Verfahren zum bekaempfen und/oder vorbeugen von allergischen krankheiten.
WO2019241742A8 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: REALTA HOLDINGS, LLC